Use of bisphosphonates in the management of postmenopausal osteoporosis
- PMID: 20946579
- DOI: 10.1111/j.1749-6632.2010.05767.x
Use of bisphosphonates in the management of postmenopausal osteoporosis
Abstract
Bisphosphonates are widely used in the treatment of postmenopausal osteoporosis. They decrease the rate of bone turnover, maintain or improve structural and material properties of bone, and increase bone mineral density and thereby decrease the risk of fractures. Available potent bisphosphonates can be given to patients by different dosing regimens that range from daily oral administration to yearly intravenous infusions. Controlled studies, extending to 10 years of continuous treatment, provide information about long-term efficacy and safety and can help in the planning of long-term treatment strategies. Selection of bisphosphonates for the treatment of individuals should be based on a careful review of efficacy data, a risk profile of the bisphosphonate, and values and preferences of the patient.
© 2010 New York Academy of Sciences.
Similar articles
-
Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.Ann Pharmacother. 2008 Jul;42(7):1085-9. doi: 10.1345/aph.1K652. Epub 2008 May 27. Ann Pharmacother. 2008. PMID: 18505912
-
Who will benefit from antiresorptive treatment (bisphosphonates)?Best Pract Res Clin Rheumatol. 2005 Dec;19(6):965-73. doi: 10.1016/j.berh.2005.06.009. Best Pract Res Clin Rheumatol. 2005. PMID: 16301190 Review.
-
Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.Clin Ther. 2005 Apr;27(4):361-76. doi: 10.1016/j.clinthera.2005.04.005. Clin Ther. 2005. PMID: 15922811 Review.
-
Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.Clin Ther. 2007 Jun;29(6):1116-27. doi: 10.1016/j.clinthera.2007.06.009. Clin Ther. 2007. PMID: 17692726 Review.
-
Improving compliance and persistence with bisphosphonate therapy for osteoporosis.Am J Med. 2006 Apr;119(4 Suppl 1):S18-24. doi: 10.1016/j.amjmed.2005.12.019. Am J Med. 2006. PMID: 16563937 Review.
Cited by
-
Treatment of complex regional pain syndrome type I with bisphosphonates.RMD Open. 2015 Aug 15;1(Suppl 1):e000056. doi: 10.1136/rmdopen-2015-000056. eCollection 2015. RMD Open. 2015. PMID: 26557377 Free PMC article. Review.
-
Bisphosphonates in the management of thalassemia-associated osteoporosis: a systematic review of randomised controlled trials.J Bone Miner Metab. 2014 Nov;32(6):606-15. doi: 10.1007/s00774-014-0584-8. Epub 2014 Apr 21. J Bone Miner Metab. 2014. PMID: 24748165
-
Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate.Drugs Aging. 2016 May;33(5):347-53. doi: 10.1007/s40266-016-0344-7. Drugs Aging. 2016. PMID: 26884390 Free PMC article. Clinical Trial.
-
Research trends and hotspots of osteoporosis and intestinal microbiota: A bibliometric analysis.Medicine (Baltimore). 2025 May 2;104(18):e41939. doi: 10.1097/MD.0000000000041939. Medicine (Baltimore). 2025. PMID: 40324264 Free PMC article.
-
Long-Term Oral Bisphosphonate Compliance Focusing on Switching of Prescription Pattern.Patient Prefer Adherence. 2020 Oct 22;14:2009-2016. doi: 10.2147/PPA.S266697. eCollection 2020. Patient Prefer Adherence. 2020. PMID: 33122894 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical